CMPX Compass Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Compass Therapeutics, Inc. (CMPX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 5, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Compass Therapeutics, Inc. (CMPX) (SEC CIK 1738021), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4/full-year 2025 earnings disclosure filed March 5, 2026 — full results in referenced exhibit, not detailed in this item text
- • Neil Lerner, Chief Accounting Officer, signed filing — no CFO signature, notable for a small-cap biotech
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Compass Therapeutics, Inc. (CMPX) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 27, 2026 | — | — | — |
8-K | Mar 5, 2026 | — | Analysis | — |
10-K | Mar 5, 2026 | Dec 31, 2025 | — | |
8-K | Jan 6, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 12, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 12, 2024 | Jun 30, 2024 | — | |
10-Q | May 13, 2024 | Mar 31, 2024 | — | |
10-K | Mar 21, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 15, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 1, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Mar 18, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 12, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 16, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 30, 2021 | Mar 31, 2021 | — | |
10-K | Mar 5, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 9, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest CMPX SEC filings in 2026?
Compass Therapeutics, Inc. (CMPX) has filed a 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did CMPX file its most recent 10-K annual report?
Compass Therapeutics, Inc. (CMPX) filed its most recent 10-K annual report on March 5, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view CMPX 10-Q quarterly reports?
Compass Therapeutics, Inc. (CMPX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every CMPX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CMPX filed recently?
Compass Therapeutics, Inc. (CMPX)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CMPX insider trading activity (Form 4)?
SignalX aggregates every CMPX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CMPX file with the SEC?
Compass Therapeutics, Inc. (CMPX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CMPX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Compass Therapeutics, Inc. (CMPX).
What is CMPX's SEC CIK number?
Compass Therapeutics, Inc. (CMPX)'s SEC CIK (Central Index Key) number is 1738021. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1738021 to look up all CMPX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find CMPX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Compass Therapeutics, Inc. (CMPX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Compass Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 34+ filings.